Glasdegib in combination with temozolomide and radiotherapy in adult patients with newly diagnosed glioblastoma: the phase Ib/II GEINO 1602 trial
Por:
Vaz-Salgado, MA, Del Barco, S, Sepúlveda, JM, Alonso, M, Pineda, E, Balana, C, Martínez-García, M and Gironés, R
Publicada:
4 dic 2025
Ahead of Print:
4 dic 2025
Resumen:
The hedgehog pathway is implicated in resistance to anticancer therapies in glioblastoma (GB). GEINO1602 (NCT03466450) phase Ib/II study evaluated the safety and efficacy of glasdegib and the Stupp scheme in newly diagnosed GB. Patients received glasdegib with radiotherapy plus concomitant and 6 cycles of adjuvant temozolomide followed by glasdegib monotherapy. The recommended phase 2 dose was 75 mg/day of glasdegib. The primary endpoint was the 15-months overall survival (OS), with a futility threshold of 60% to consider the trial positive; accrual required 70 evaluable patients. 79 patients were enrolled. The 15 m OS rate was 52.1% (95% CI: 41.7-65.2). At 2 years, 29.2% of the patients were still alive. The median progression-free survival (PFS) was 7.1 months (95% CI: 6.2-8.6). Glasdegib plus chemoradiotherapy show preliminary efficacy. Despite not surpassing the futility threshold, 30% lived at the data cutoff. Translational research will help define the molecular traits of long-term survivors.
Filiaciones:
Vaz-Salgado, MA:
Hosp Univ Ramon & Cajal, Inst Ramon & Cajal Invest Sanitaria Irycis, Med Oncol Dept, Biomarkers & Personalized Approach Canc Grp BioPAC, Madrid, Spain
Del Barco, S:
Inst Catala Oncol Girona, Med Oncol Dept, Girona, Spain
Sepúlveda, JM:
Hosp Univ 12 Octubre, Med Oncol Dept, Madrid, Spain
Alonso, M:
Hosp Virgen Rocio, Med Oncol Dept, Seville, Spain
Pineda, E:
IDIBAPS, Med Oncol Dept Hosp Clin & Translat Genom & Target, Barcelona, Spain
:
Inst Catala Oncol, Med Oncol Dept, Badalona, Spain
Martínez-García, M:
Hosp del Mar, Med Oncol Dept, Barcelona, Spain
Gironés, R:
Hosp Univ & Politecn La Fe, Med Oncol Dept, Valencia, Spain
Green Submitted, gold
|